BBLG Regains Nasdaq Compliance for Continued Listing | BBLG Stock News

Bone Biologics (BBLG, Financial) has successfully met the Nasdaq’s minimum bid price requirement, as per the notification received from The Nasdaq Stock Market. This compliance aligns with Nasdaq Listing Rule 5550(a)(2), ensuring BBLG’s continued presence on the Nasdaq Capital Market. With this achievement, Bone Biologics is now fully compliant with all necessary listing standards, allowing its common stock to remain on the Nasdaq Capital Market. This development marks a positive step for the company in maintaining its market position.

Wall Street Analysts Forecast

Based on the one-year price targets offered by 1 analysts, the average target price for Bone Biologics Corp (BBLG, Financial) is $22.50 with a high estimate of $22.50 and a low estimate of $22.50. The average target implies an upside of 440.87% from the current price of $4.16. More detailed estimate data can be found on the Bone Biologics Corp (BBLG) Forecast page.

Based on the consensus recommendation from 1 brokerage firms, Bone Biologics Corp’s (BBLG, Financial) average brokerage recommendation is currently 2.0, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

MORE IN INSIDE INVESTMENT NEWS

Citigroup beats second-quarter estimates as markets and banking revenues jump

Published: Tuesday, July 15, 2025 · 12:38 PM

JPMorgan Chase tops estimates on stronger-than-expected trading, investment banking

Published: Tuesday, July 15, 2025 · 11:25 AM